List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
29 January 2015 | By AstraZeneca
AstraZeneca has announced 4 research collaborations aimed at harnessing CRISPR, a pioneering genome-editing technique, across its entire discovery platform...
7 November 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue...
3 November 2014 | By Almirall
Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied...
20 October 2014 | By AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership...
10 October 2014 | By AstraZeneca
AstraZeneca announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell...
29 September 2014 | By AstraZeneca
AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid...
25 September 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK...
23 September 2014 | By GlobalData
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData...
17 September 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain...
8 September 2014 | By AstraZeneca
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress...
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
1 September 2014 | By AstraZeneca
Results are in line with new ESC/EACTS 2014 Guidelines on Myocardial Revascularisation which give a class I recommendation to start dual antiplatelet therapy in STEMI patients at first medical contact...
26 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
19 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
